Floatz logo

Tivozanib

Carcinoma, Renal Cell

AVEO Pharmaceuticals, Inc.Small moleculePhase 3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
89/ 100

Competitive context

298 Active assets in the Carcinoma, Renal Cell cohort.

Asset / SponsorPhaseRating
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Tivozanib is also rated in:

renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
nonpapillary renal cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →